ArticleBritish journal of cancer2016

Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.

D Mahalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.